In Episode 168 of the No Limitations Podcast, Crash or Crash Through, Blenheim Partners’ Gregory Robinson speaks with David Williams, Chairman of Kidder Williams Ltd.

In a stimulating and thought-provoking conversation, David shares his stories and explores the evolution of investment banking in Australia and the critical role capital plays in scaling innovative businesses. He also shares firsthand perspectives on high‑profile transactions across pharmaceuticals, medical devices, and agribusiness, and reflects on the strategic decisions behind building globally competitive companies from Australia. He also offers his perspective on the Australian Federal Budget and where the nation stands economically, highlighting the opportunities and challenges shaping the country’s landscape. David further discusses the realities of principal investing, leadership in complex markets, and what it takes to turn breakthrough medical technologies into commercially successful and life‑saving products.

David is one of Australia’s most prominent investment bankers in healthcare and agriculture, with decades of experience advising leading companies on mergers and acquisitions, capital raising, and strategy. He has played a pivotal role in landmark transactions, including the return of Vegemite to Australian ownership, the sale of SPC, and the global rollout of innovative medical technologies such as the Green Whistle pain relief device and PolyNovo Ltd’s wound care platform. He has also built a strong track record as a principal investor, helping transform businesses such as Tassal Group and Medical Developments International Ltd into global success stories, while contributing to the growth of life‑saving medical innovations.

Alongside his advisory and investment work, David has had an extensive board career, serving as Chairman and Director across a wide range of public and private companies. He is currently Chairman of Kidder Williams Ltd, where he was the former Managing Director, Seminal Artist Group, Mobile Tyre Shop, RMA Global Ltd and Arovella Therapeutics Ltd and has previously held chairmanships at PolyNovo Ltd, INOVIQ Ltd, Tassal Group, Clever Communications Australia Ltd and Medical Developments International Ltd. He also held various Non-Executive Director roles spanning multiple sectors including healthcare, technology, consumer, and agriculture, reflecting a deep expertise in governance, growth, and strategic transformation. David has also held senior M&A leadership roles at Societe Generale, Challenger Corporate Finance, SG Hambros, ANZ McCaughan, and Arthur Andersen, and was recognised as Chairman of the Year 2017 by Biotech Daily.

Please note: this episode was recorded on 14 May 2026.

See omnystudio.com/listener for privacy information.